Pentadecanoic acid, a saturated odd-chain fatty acid known as C15, has drawn growing scientific attention for its potential roles in metabolic and cellular health. Found naturally in full-fat dairy products and the fat of ruminant animals, it has historically been overlooked in nutrition research. More recently, researchers at Epitracker have proposed that C15 may function as an essential fatty acid, a classification not yet formally adopted by regulatory bodies, based on its integration into cell membranes and a range of proposed biological activities.
Among the areas being explored is mental health: specifically, whether C15 might influence mood, anxiety, and cognitive function through its effects on inflammation, cellular aging, and mitochondrial activity. This article summarizes what the available published research suggests, where the evidence is genuinely limited, and what remains speculative. Nothing here constitutes medical advice, and the FDA has not evaluated C15 for the treatment or prevention of any mental health condition.
Key Takeaways
- C15 shows biologically plausible connections to brain health through PPAR receptor activation, anti-inflammatory activity, and anti-ferroptotic properties in cell and animal research [1][2].
- No human clinical trials have tested C15 specifically for depression or anxiety; current evidence is preliminary and mechanism-based.
- A 2025 paper on archived Navy dolphin brains reported amyloid plaques rising with age, and separately a lab screen found C15 inhibited two brain-related enzymes; no C15 was given to any dolphin, and the authors are co-founders of companies that commercialize C15 [2].
- Human milk phospholipid research suggests lipid quality matters for long-term cognitive development, though C15 is one component among many [3].
- In the one small randomized trial of C15 alone (30 adults, 200 mg a day for 12 weeks, industry-supported), no significant adverse events were reported; the FDA has not approved C15 for any mental health indication [5].
What Is C15 and How Might It Affect the Brain?
Pentadecanoic acid (C15) is a 15-carbon saturated fatty acid that differs structurally from the even-chain saturated fats more commonly discussed in nutrition. Unlike palmitic acid (C16:0), which is associated with cellular inflammation at high doses, C15 is an odd-chain fatty acid that behaves differently once incorporated into cell membranes. Researchers have proposed that its integration into membranes may improve their structural integrity and reduce fragility: a property potentially relevant to neuronal cell health.
Two mechanisms are most frequently cited in connection with brain and mood function. First, C15 appears to act as a partial agonist at PPAR-alpha and PPAR-delta receptors, which regulate fat metabolism and inflammatory signaling. These receptors are expressed in brain tissue and have been linked to mood regulation and neuroinflammation. Second, C15 has been studied in the context of ferroptosis, a form of iron-dependent cell death associated with oxidative stress, and cellular senescence, both of which are implicated in aging-related cognitive decline. These mechanisms are proposed based on laboratory and cell-based research, not established clinical pathways.
Cell-Based Evidence: Activity Across Disease-Relevant Systems
A 2022 study published in PloS One evaluated C15 across twelve primary human cell-based disease systems, comparing its activities to omega-3 fatty acids [1]. The authors, who are linked to a company that sells a C15 product, reported that C15 was not cytotoxic at any tested concentration while the omega-3 EPA was cytotoxic to four cell systems at 50 µM, and that C15 had activities EPA did not share. This is a cell screen, not a head-to-head result in people [1]. Among the areas showing activity were pathways relevant to immune function, metabolic regulation, and cellular aging. The authors noted that C15 activated PPAR-alpha and PPAR-delta receptors and showed anti-ferroptotic properties, meaning it appeared to reduce a form of cell death linked to iron overload and oxidative damage [1].
Every mood-related C15 finding so far is from cells or enzyme tests
Pattern like bupropion
At 5.6 µM, C15:0 had cell-based properties similar to the antidepressant bupropion (Pearson score 0.78).
Blocks FAAH and MAO-B
C15:0 inhibited FAAH (IC50 2.5 µM) and MAO-B (IC50 19.4 µM) in a cell-free screen.
Cannabinoid receptors
A C15:0 metabolite activated CB1 and CB2 receptors (EC50 3.7 and 3.2 µM).
C15 has lab hints about brain chemistry, but no trial has shown it improves mood.
Lab studies by authors linked to companies that sell C15:0; results in cells often do not carry over to people. Source: PLoS ONE 2022; International Journal of Molecular Sciences 2025; Scientific Reports 2022.
Chart: c15hub.com: Every mood-related C15 finding so far is from cells or enzyme tests
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Research note: In a lab study, C15:0 at 5.6 µM had cell activity patterns similar to the antidepressant bupropion (Pearson score 0.78). This is pattern matching in cell assays, not evidence it treats depression [1].
While this study did not measure mood or cognition directly, the cell systems studied included pathways connected to neuroinflammation and mitochondrial function. Mitochondrial dysfunction has been linked to depression and fatigue in some clinical research, but that is not evidence that C15 changes it. The PPAR pathways activated by C15 are also involved in regulating neuroinflammatory responses. These connections are biologically plausible, but translating cell-based findings to human mental health outcomes requires significantly more research.
C15 and Neurodegeneration: Insights From a Dolphin Model
One of the more unusual bodies of evidence comes from research on bottlenose dolphins. A 2025 study in the International Journal of Molecular Sciences examined aging-associated amyloid-beta plaques and neuroinflammation in bottlenose dolphins (Tursiops truncatus), which develop Alzheimer’s-like brain changes as they age [2]. The researchers identified C15 as having novel cognitive health-supporting roles based on its activity in the context of neuroinflammation and amyloid pathology [2].
The study is noteworthy because dolphins, like humans, are long-lived mammals with complex social cognition, making them a biologically relevant model for certain aspects of aging-related brain disease. In that paper the C15 link comes from a screening assay, described below, not from giving C15 to any animal. However, animal and comparative biology findings do not translate automatically to human clinical outcomes. This research is hypothesis-generating, not confirmatory of benefit in humans.
The connection to depression and anxiety specifically is indirect: neuroinflammation is increasingly recognized as a contributing factor in mood disorders, particularly treatment-resistant depression. If C15 does modulate neuroinflammatory pathways as proposed, that could theoretically be relevant to mood. But this chain of reasoning requires human clinical validation before any claims can be made.
What the Dolphin Study Measured, and What It Did Not
The 2025 paper did two separate things. The first half is descriptive pathology: quantitative immunohistochemistry on 68 tissue samples from the archived brains of 19 Navy dolphins. As in humans, plaque density varied most in the hippocampus (90th percentile of 4.95 plaques per square millimeter), plaque density increased with age (p = 0.05), and every neuroinflammation marker measured was detected, with activated microglia highest in the hippocampus (0.46 ± 0.38 cells per square millimeter). That half does not involve C15.[2]
The second half is a different kind of experiment: a third-party panel intended to screen for potential Alzheimer’s therapeutics. C15 was a dose-dependent inhibitor of two targets, fatty acid amide hydrolase (FAAH; half-maximal inhibitory concentration 2.5 micromolar, 89 percent maximum inhibition at 50 micromolar relative to the reference inhibitor URB597) and monoamine oxidase B (MAO-B; 19.4 micromolar, 70 percent maximum inhibition at 50 micromolar relative to R(-)-deprenyl). The authors suggested C15 may support cognitive health, especially at higher concentrations.[2] An assay in a screening well is not a change in a brain, and the study did not measure plaques, inflammation or cognition after any C15 treatment, so the two halves sit side by side and suggest a hypothesis without testing it. The lead author is a co-founder of and employed by companies that hold licensing rights to commercialize odd-chain fatty acids, which is disclosed in the paper.
An Odd-Chain Oil in a Worm Model of Alzheimer’s Disease
A 2026 study in Molecules took a different route, testing an odd-chain-fatty-acid-enriched algal oil in Caenorhabditis elegans, a roundworm used for fast neurodegeneration screening. Triglycerides made up 97.3 percent of the oil’s lipid content, and triglycerides containing C15:0 or C17:0 accounted for more than 90 percent of the triglyceride species, so the test material was genuinely odd-chain dominant. The effects were selective: locomotor function improved significantly in the Alzheimer’s model worms, Parkinson’s model deficits improved moderately, and Huntington’s model worms showed no benefit.[4]
Untargeted metabolomics of its key component, C15:0, pointed to energy metabolism. C15 generates propionyl-CoA through beta-oxidation, which can replenish the tricarboxylic acid cycle, and impaired cerebral energy metabolism is a core feature of Alzheimer’s disease. The authors also reported upregulated membrane phospholipids and broad changes across amino acid, cofactor, nucleotide and carbon metabolism pathways. Two of the authors disclosed research grants from a company with an interest in the oil, which the paper states had no role in the study.[4] A worm’s locomotor score is not memory, and there is no human trial of C15 for cognition or Alzheimer’s risk. These studies mark where researchers might test next, not a basis for a personal decision, and anyone worried about memory or cognition should raise it with a physician.
Early Life Nutrition, Brain Phospholipids, and C15
A 2025 study in the European Journal of Nutrition investigated the long-term cognitive benefits of human milk phospholipids in breastfed children assessed at preschool age, as part of the MUAI study [3]. The research found associations between phospholipid exposure through breast milk and cognitive outcomes measured years later [3]. Human breast milk contains C15 among its lipid components, and phospholipids derived from milk fat globule membrane are recognized for their roles in early brain development.
This study does not isolate C15 as the operative component, the effects measured were attributed to the phospholipid fraction broadly, but it does not show that odd-chain fatty acids matter for brain development, and one breast-milk cohort linked higher milk C15 at 42 days to lower infant motor development scores [7][3]. The relevance to adult mental health is extrapolated rather than direct. Early developmental windows differ substantially from adult supplementation contexts.
What Does This Mean for Depression and Anxiety Specifically?
To be direct: no published human clinical trial has tested C15 supplementation as a treatment or preventive intervention for depression or anxiety. The pathway from the available evidence to those conditions runs through proposed mechanisms (PPAR activation, reduced neuroinflammation, anti-ferroptotic effects) that are biologically plausible but not yet demonstrated in human mood disorder research.
The case for a potential connection rests on several observations in the broader literature: chronic low-grade neuroinflammation is associated with depressive symptoms; mitochondrial dysfunction appears in both depression and anxiety disorders; and dietary fat quality influences brain membrane composition, which in turn affects neurotransmitter signaling. C15’s proposed roles in each of these areas make it a reasonable candidate for future study. That is meaningfully different from evidence that it helps.
Observational data linking low dairy fat intake with higher rates of depression in some populations has been noted in nutritional epidemiology, but such associations are confounded by dozens of dietary and lifestyle variables and do not establish C15 as the causative factor. Anyone managing depression or anxiety should work with a qualified clinician rather than rely on emerging nutrient research as a primary strategy.
Safety Profile and Studied Doses
The one small randomized trial of C15 alone (30 adults, 200 mg a day for 12 weeks, supported by the company that supplied the capsules) reported no significant adverse events [5][1]. The capsules in the one 12-week trial were supplied by the sponsoring company, which says its ingredient is made by chemical synthesis rather than extracted from dairy or fish [5][6]. Food sources include butter, cheese, whole milk, and the fat of grass-fed ruminants, where C15 concentrations vary depending on the animal’s diet.
Because this is a relatively new area of supplement research, long-term safety data beyond the periods studied are not yet available. People on medications (particularly those affecting lipid metabolism, PPAR pathways, or immune function) should consult a healthcare provider before adding C15 supplements. Pregnant or breastfeeding individuals and those with existing metabolic or liver conditions should also seek medical guidance.
🛒 Where to Buy Pentadecanoic Acid (C15)
- Fatty15 (official site) 20% off with code SFKKDBQQ
capsules, 100 mg C15 per capsule; 1 capsule/day starter, 2 capsules/day maintenance: Category creator, from the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15
capsules, 200 mg C15 per serving (2 capsules): Generic C15 supplement; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15
softgels, 100 mg C15 per softgel: Established supplement brand with strong Amazon presence; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15)
powder, 100 to 300 mg per measured serving: Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. C15 products vary widely in how much pentadecanoic acid they actually contain, so check that the Supplement Facts panel lists C15 in milligrams as its own line item rather than bundling it into a fatty acid blend, and that the per-serving dose falls in the 100 to 300 mg range used in published research.
A Note on the Evidence
The evidence connecting C15 to mental health outcomes is preliminary, consisting primarily of cell-based and animal research with no human clinical trials yet completed for depression, anxiety, or cognitive function specifically; individuals with mental health conditions, those on psychiatric or metabolic medications, and pregnant or breastfeeding individuals should consult a qualified healthcare provider before considering C15 supplementation.
Frequently Asked Questions
Can C15 treat depression or anxiety?
No published human clinical trial supports C15 as a treatment for depression or anxiety. The available research is cell-based and animal-based, with proposed mechanisms that are biologically interesting but not yet validated in human mood disorder trials [1][2]. Anyone experiencing depression or anxiety should consult a qualified mental health professional.
What mechanisms might connect C15 to brain health?
Researchers propose that C15 acts as a partial PPAR-alpha and PPAR-delta agonist, which could modulate neuroinflammatory signaling, and that it may reduce ferroptosis: a form of oxidative cell death relevant to neuronal health [1]. It also integrates into cell membranes, potentially improving their structural stability. These mechanisms are proposed from laboratory evidence, not confirmed in human brain health studies.
Why was C15 studied in dolphins?
Bottlenose dolphins develop aging-associated amyloid-beta plaques and neuroinflammation similar to Alzheimer’s disease in humans, making them a biologically relevant comparative model for age-related cognitive decline [2]. Researchers identified C15 as potentially supporting cognitive health in this context, though findings in dolphins require further investigation before conclusions about human application can be drawn.
Is C15 found in breast milk, and does that relate to cognitive development?
Human breast milk contains C15 as part of its lipid fraction, including milk fat globule membrane phospholipids. A 2025 study found long-term cognitive benefits associated with human milk phospholipid exposure in children assessed at preschool age, suggesting lipid quality in early nutrition matters for brain development [3]. However, the study examined the phospholipid fraction broadly, not C15 in isolation.
Is C15 truly an 'essential' fatty acid?
The classification of C15 as an essential fatty acid is a hypothesis advanced by Epitracker researchers based on observational associations and mechanistic studies [1]. It has not been formally adopted by regulatory bodies, mainstream nutrition science organizations, or the FDA. This designation remains scientifically debated and should be understood as a research hypothesis, not established nutritional science.
What doses have been studied, and are they safe?
Research on C15 supplementation has primarily used doses of 100 to 300 mg per day. In the one small industry-supported randomized trial (30 adults, 200 mg a day for 12 weeks), no significant adverse events were reported [5][1]. Long-term safety data beyond studied periods are limited, and individuals with metabolic conditions, those on relevant medications, or those who are pregnant or breastfeeding should consult a healthcare provider before supplementing.
References
- Venn-Watson SK et al. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PloS one (2022). PMID 35617322
- Venn-Watson S et al. Aging-Associated Amyloid-β Plaques and Neuroinflammation in Bottlenose Dolphins (Tursiops truncatus) and Novel Cognitive Health-Supporting Roles of Pentadecanoic Acid (C15:0). International journal of molecular sciences (2025). PMID 40332352
- Yang MT et al. Long-term cognitive benefits of human milk phospholipids in breastfed children at preschool age: results from MUAI study. European journal of nutrition (2025). PMID 40986082
- Mu Q et al. Odd-Chain Fatty Acids-Enriched Algal Oil Improves Locomotor Function and Modulates Metabolic Pathways in Caenorhabditis elegans Model of Alzheimer’s Disease. Molecules (2026). PMID 42197288
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- Fatty15 (Seraphina Therapeutics) Fatty15 FAQs. Fatty15 (Seraphina Therapeutics) (2026). source
- Bi Y et al. Odd- and branched-chain fatty acids in breast milk and neurodevelopment in early infancy: a prospective cohort study. European journal of nutrition (2026). PMID 42965676
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.